- SATRAPLATIN REDUCES RISK OF PROSTATE CANCER PROGRESSION.

GPC Biotech AG (Frankfurt Stock Exchange: GPC; TecDAX index; NASDAQ: GPCB) and Pharmion Corporation (NASDAQ: PHRM) have announced that final progression-free survival (PFS) results for ......
- APPROVAL FOR U.K. CLINICAL TRIAL FOR REOLYSIN.

Oncolytics Biotech Inc. ("Oncolytics") (TSX: ONC, NASDAQ: ONCY), Calgary, Canada, has received a letter of approval from the U.K. Medicines and Healthcare products Regulatory Agency ......
- Heat triggers tumor-killing drug.(INDUSTRYNews)

Researchers at Duke University have begun testing encapsulated chemotherapy drugs using a thermal system that provides precision heat therapy in women whose breast cancers have ......
- Genentech, Inc.

1 DNA Way South San Francisco, CA 94080-4990 650-225-1000 www.gene.com Genentech BioOncology continued to make significant progress in 2001. Combined product sales of Herceptin and ......
- LORUS' VIRULIZIN EFFECTIVE AGAINST PANCREATIC TUMORS.

Lorus Therapeutics Inc. (TSE:LOR.) (OTCBB:LORFF), Toronto, has announced that its lead anti-cancer drug, Virulizin(R) has demonstrated strong anti-tumor activity in mice containing human pancreatic tumor ......
- Changing the way the world views cancer: scientists at Moffitt Cancer...

MOFFITT SCIENTISTS: ACCELERATING THE FUTURE OF CANCER RESEARCH "The disease of cancer will be banished from life by calm, unhurrying, persistent men and women, and ......
- Changing the way the world views cancer. (Special Advertising Report).

Scientists at Moffitt Cancer Center are employing new advances in functional genomics, molecular targeting, anti-cancer vaccines and genetic testing to make significant improvements in the ......
- ABLYNX AND GENENCOR FORM ONCOLOGY COLLABORATION.

Ablynx, Ghent, Belgium, a pioneer in the discovery and development of Nanobodies, a new class of therapeutic antibodies, has entered into an oncology drug discovery ......
- FERX AND JAPAN'S NCCRI COLLABORATE ON GENE THERAPY.

FeRx Inc., San Diego, and the National Cancer Center Research Institute (NCCRI) of Japan have established a research collaboration designed to develop a novel tumor-targeting ......
- PROGEN'S FIRST U.S. CLINICAL TRIAL WITH PI-88 BEGINS.

The first two patients have been enrolled in Progen Industries Limited (Nasdaq:PGLAF) (ASX:PGL), Brisbane, Australia, Phase I/II trial of anti-cancer drug PI-88. The trial, which ......